Search for a trial

A PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, MULTICENTER STUDY TO EVALUATE MAINTENANCE OF RESPONSE, SAFETY AND PATIENT REPORTED OUTCOMES IN ACROMEGALY PATIENTS TREATED WITH OCTREOTIDE CAPSULES, AND IN PATIENTS TREATED WITH STANDARD OF CARE PARENTERAL SOMATOSTATIN RECEPTOR LIGANDS WHO PREVIOUSLY TOLERATED AND DEMONSTRATED A BIOCHEMICAL CONTROL ON BOTH TREATMENTS

* To assess maintenance of biochemical control of octreotide capsules compared to parenteral SRLs in patients with acromegaly, who previouslydemonstrated biochemical control on both treatments.* To assess symptomatic response to octreotide capsules…

A Multi-Center, Prospective Study of the Wall Flex ® RX Biliary Fully Covered Stent for the Treatment of Benign Biliary strictures

Primary Objective: To assess the safety and performance of temporary placement of the Wall Flex Biliary RX as a Fully Covered Stent Treatment of Biliary obstruction that result from benign bile duct strictures.

A Phase 3, Randomized, Double-­Blind, Placebo-­Controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Previously Tolerated and Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment

- To assess maintenance of biochemical control with octreotide capsules compared to placebo in patients with acromegaly, who previously demonstrated biochemical control on SRLs.- To assess maintenance of biochemical control, based on GH, with…

[18F]mFBG PET-CT imaging of pheochromocytoma

This study has been transitioned to CTIS with ID 2024-513622-35-00 check the CTIS register for the current data. The primary objective of this study is to assess the number of detected pheochromocytoma lesions, proved by histology, with [18F]mFBG…

Focus on values to stimulate shared decisions in patients with thyroid cancer: A multifaceted
COMmunication BOoster (COMBO)*

Aim: to develop, implement and evaluate COMBO to improve SDM during the treatment trajectory of TC patients in situations when clear cut recommendations cannot be made either because the benefits closely balance with risks, or because this balance…

A randomized placebo-controlled study in patients with a Gallium-68 DOTATATE PET/CT positive, clinically non-functioning pituitary macroadenoma (NFMA) of the effect of Lanreotide autosolution on Tumor (adenoma) size

To investigate the efficacy of lanreotide therapy as compared to placebo in patients with NFMA and positive pituitary somatostatin receptor imaging using Gallium-68 DOTATATE PET/CT, on tumor size.

CXCR4-directed [68Ga]Ga-PentixaFor PET/CT vs AVS performance in a diagnoStic randomized Trial Ultimately comparing hypertenSion outcome in primary aldosteronism

This study has been transitioned to CTIS with ID 2024-512628-12-00 check the CTIS register for the current data. Primary objectives-To assess the concordance between [68Ga]Ga-PentixaFor PET/CT and AVS for identification and/or lateralization of APAs…

Phase II Study of cisplatin and everolimus in patients with metastatic or unresectable neuroendocrine carcinomas (NEC) of extrapulmonary origin

Neuroendocrine carcinomas are distinguished clinically from neuroendocrine tumours by their rapid growth and early development of metastases. Both large and small cell neuroendocrine carcinomas are generally treated based upon chemotherapy regimens…